Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MP2021
- Development stage
- Preclinical
- Lead developer
- MedPacto
- Modality
- Small Molecules
01
Overview
MP2021 is a preclinical-stage small molecule drug candidate developed by MedPacto. It specifically targets Transmembrane 4 L6 family member 19 (TM4SF19), a protein that is highly expressed in osteoclasts and plays a critical role in their differentiation and bone-resorbing activity. By inhibiting TM4SF19, MP2021 aims to suppress excessive bone resorption, which is a hallmark of various metabolic and inflammatory bone diseases. The drug is being developed for the treatment of osteoporosis, inflammatory arthritis, and bone metastatic disease, with the goal of preventing bone destruction and maintaining bone density.
02
Targets
TM4SF19 (Transmembrane 4 L6 family member 19)
Beyond the preview
Go deeper on MP2021.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MP2021.